Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Gilead Sciences, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Gilead Sciences, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. NASTAD appears in 1 tracked Biotech story from March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NASTAD. Shared-story counts are live from our verified record — not editorial picks.
New Limits Reported
States begin implementing restrictive eligibility and waitlists for drug assistance programs.
Fiscal Pressure Mounts
Rising costs of long-acting therapies and expiration of pandemic funding strain state budgets.
Waitlist Peak
National ADAP waitlists reached a record high of over 9,000 individuals following the Great Recession.
Ryan White CARE Act
Federal legislation established to provide a safety net for HIV/AIDS care and treatment.
Several states have begun implementing restrictive eligibility requirements and waitlists for AIDS Drug Assistance Programs (ADAPs), citing budgetary shortfalls and rising medication costs. This shift threatens to reverse years of progress in HIV viral suppression and places significant financial pressure on low-income patients and safety-net providers.
NASTAD is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
